69214-09-1

Basic information

• Product Name: 5-BROMO-IMIDAZO[1,2-A]PYRIDINE
• Synonyms: 5-BROMO-IMIDAZO[1,2-A]PYRIDINE;5-BROMOIMIDAZO[1,2-A]PYRIDINE, 95+%;5-bromoH-imidazo[1,2-a]pyridine;5-BROMO-5H-IMIDAZO[2,1-B][1,3]OXAZINE;5-Bromo-1,5-dihydroimidazo[1,2-a]pyridine
• CAS NO: 69214-09-1
• Molecular Formula: C₇H₅BrN₂
• Molecular Weight: 197.03
• EINECS: 1592732-453-0
• Product Categories: API intermediates;Building Blocks;Imidazo[x,x-y]pyridine;Heterocycle-Pyridine series
• Mol File: 69214-09-1.mol
• Article Data: 6

Chemical Properties

• Melting Point: 61-64℃
• Appearance: /
• Density: 1.697 g/cm³
• Refractive Index: 1.688
• Storage Temp.: Room temperature.
• Solubility: Chloroform (Slightly), DMSO (Slightly)
• PKA: 5.15±0.50(Predicted)
• CAS DataBase Reference: 5-BROMO-IMIDAZO[1,2-A]PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-IMIDAZO[1,2-A]PYRIDINE(69214-09-1)
• EPA Substance Registry System: 5-BROMO-IMIDAZO[1,2-A]PYRIDINE(69214-09-1)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 69214-09-1(Hazardous Substances Data)

Usage

Uses

5-Bromoimidazo[1,2-a]pyridine can be used as HPK1 antagonists to treat HPK1-mediated disorders.

InChI:InChI=1/C7H5BrN2/c8-6-2-1-3-7-9-4-5-10(6)7/h1-5H

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 
• 107-20-0 2-chloroethanal 
• 19798-81-3 2-Amino-6-bromopyridine 
• 603301-13-9 5-bromoimidazo[1,2-a]pyridine hydrobromide 
• 17157-48-1 bromoacetaldehyde 

Downstream Products

• 952511-72-7 imidazo[1,2-a]pyridine-5-carbonitrile 
• 1613167-94-4 C₂₉H₃₀F₃N₅O₂ 
• 1257384-45-4 1-((2-(imidazo[1,2-a]pyridin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,N-dimethylpiperidin-4-amine 
• 1257384-56-7 2-(1-((2-(imidazo[1,2-a]pyridin-5-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol 
• 1257384-58-9 4-(5-(imidazo[1,2-a]pyridin-5-yl)-2-((3-morpholinoazetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine 
• 1257384-57-8 2-(1-((5-(imidazo[1,2-a]pyridin-5-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)piperidin-4-yl)propan-2-ol 
• 1257384-44-3 4-(1-((2-(imidazo[1,2-a]pyridin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-yl)morpholine 
• 1257384-49-8 2-(4-((2-(imidazo[1,2-a]pyridin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide 
• 1257384-55-6 2-(4-((2-(imidazo[1,2-a]pyridin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide 
• 1040277-30-2 tert-butyl 6-(imidazo[1,2-a]pyridin-5-yl)-2,2,4-trimethyl-2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-3-one-1-carboxylate 
• 198896-16-1 ethyl (imidazo[1,2-a]pyridin-5-ylthio)acetate 
• 111753-13-0 3-nitro-5-triphenylphosphoranylideneimidazo<1,2-a>pyridine 
• 111753-11-8 3-nitro-5-tris(dimethylamino)phosphoranylidenetriazenoimidazo<1,2-a>pyridine 
• 111753-12-9 3-nitro-5-tris(dimethylamino)phosphoranylideneaminoimidazo<1,2-a>pyridine 

Relevant articles and documents

Double head-to-tail direct arylation as a viable strategy towards the synthesis of the aza-analog of dihydrocyclopenta[hi]aceanthrylene-an intriguing antiaromatic heterocycle

The first case of double head-to-tail direct arylation of aromatic compounds and the unusual photophysical properties of the resulting 2,2a1,5b1,7-tetraazacyclopenta[hi]aceanthrylene are reported. This molecule, comprising of two imidazo[1,2-a]pyridine units, is antiaromatic due to the changes in the efficiency of π-electron ring current and it belongs to a class of seldom encountered compounds with a dark lowest electronically excited singlet state.

IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES

A compound of formula (I) wherein Ring A is imidazol[1,2a]pyrid-3-yl or pyrazolo[2,3a]pyrid-3-yl; Ris as defined within; m is 0-5; wherein the values of Rmay be the same or different; Ris as defined within; n is 0 to 2, wherein the values of Rmay be the same or different; Ring B is phenyl or phenyl fused to a C5-7cycloalkyl ring; Ris as defined within; p is 0-4; wherein the values of Rmay be the same or different; Ris as defined within; q is 0-2; wherein the values of Rmay be the same or different; and wherein p+q=5; or a pharmaceutically acceptable salt or an in vivo hydrolyzable ester thereof is described. The use of compounds of formula (I) in the inhibition of cell cycle kinases CDK2, CDK4, and CDK6 are also described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are detailed.

PURINE DERIVATIVES AS KINASE INHIBITORS

The present invention provides kinase inhibitors of Formula I.